Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

NCT02902965 is registered in ClinicalTrials.gov with Pharmacyclics Switzerland GmbH as lead sponsor.

NCT NCT02902965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02902965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Lead sponsor
Pharmacyclics Switzerland GmbH
Phase
Phase 2
Overall status
Completed
Start date
September 20, 2016
Completion date
October 26, 2018
Enrollment
74 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma